Recently, Ignis Therapeutics (“Ignis”) and NeuroSigma, Inc. (“NeuroSigma”) announced that Ignis had obtained from NeuroSigma an exclusive license to research and commercialize the Monarch eTNS System® for treatment of attention deficit hyperactivity disorder (“ADHD”) in mainland China, Hong Kong and Macao. In consideration of the granting of the license, Ignis would pay NeuroSigma a large down payment, various milestone payments of up to USD 10 million, sales commissions and other considerations.
Monarch eTNS System® is the first medical device for the non-pharmacological treatment of ADHD approved by The U.S. Food and Drug Administration (FDA).
NeuroSigma is a biotechnology company focused on the central nervous system (CNS). It is committed to developing innovative therapies in the CNS field.
NeuroSigma is a California-based life sciences company focused on developing bioelectronic technologies to transform medical practices and patients’ lives.
JunHe was appointed by Ignis to review and revise the documents for this transaction. JunHe has vast experience in pharmaceutical licensing transactions and provided professional, meticulous and efficient legal services, which was highly recognized by the client.
The project was led by Dr. WANG, Zhaohui (Zoe) and undertaken by ZHAO, Hao (Gerry).